Intelligencia AI

Intelligencia AI leads the way in de-risking clinical development with AI, offering a suite of solutions that de-risk high-stakes decisions in drug development. The company positions its tools to help life sciences organizations assess the probability of success, support portfolio planning, and guide licensing decisions using AI-informed insights. The focus is on combining data science with biomedical expertise to inform strategic choices across development programs.

Intelligencia AI delivers real-time, curated data and explainable AI to support decision-making in pharmaceutical development. By standardizing data and providing transparency into which features drive results, the tools aim to make clinical and business decisions more reliable and auditable. The approach emphasizes trusted AI with visibility into how predictions are generated and why they matter.

The portfolio includes AI-powered solutions built on comprehensive data and proprietary ontologies, designed to standardize risk evaluation across entire portfolios. The company highlights harmonized data for consistent risk assessment, and emphasizes the ability to de-risk clinical development and enhance decision-making with probability-of-success insights.

Intelligencia AI states plans and capabilities around data-driven platform offerings for drug development risk management, including SaaS tools and data-as-a-subscription services. It references collaborations with major pharma organizations and emphasizes integration-ready data, explainability, and ongoing updates to data and models.

Use cases

• De-risk clinical development and enhance decision-making with AI-driven probability of success.
• Benchmark predictions against historical data to inform strategy and investments.